More importantly, pre-treatment with S-ELNs protected mice from GalN/LPS-triggered acute liver damage; therefore, S-ELNs represent a promising new bioactive agent with the potential for the treatment of FHF. Here, GAL is linked to TNF receptor 1-associated periodic fever syndrome.